Baudax Bio

Baudax Bio Inc, a spin-out of Recro Pharma's acute segments, is focused on the development and commercialization of therapeutics for the potential treatment of post-operative pain and anaesthesia.In June 2023, Baudax Bio Inc announced the aquisition of TeraImmune Inc.In November 2019, the spin-out of Baudax Bio from Recro pharma was completed.In April 2023, Baudax Bio Inc declared in its public offering priced 3,478,262 shares of its common stock and the related common stock purchase warrants at a price of $1.15 per share.. In May 2023, Baudax Bio Inc closed public offering.In December 2022, the company priced a public offering of Series A-3 warrants to purchase up to 1,042,787 shares of common stock and Series A-4 warrants to purchase 1,042,787 shares of common stock, at a combined public offering price of $4.795 per share.In September 2022, Baudax Bio Inc had announced that its Board of Directors declared a dividend of one one-thousandth of a share of ne